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Abstract
FIPV16-positive oropharyngeal cancer (OPC) patients experience better outcomes compared to HPV16-negative
patients. Currently, strategies for ffeatment de-escalation are based on HPV status, smoking history and disease
stage. However, the appropriate cut-point for smoking and the role of other non-clinical factors in OPC survival
remains uncertain. We examined factors associated with OPC outcome in 32 I patients recruited in a large European
multi-center study. Seropositivity for HPVI6 E6 was used as a marker of FIPVl6 positive cancer. Hazard ratios (HR)
and confidence intervals (CI) were estimated using Cox proportional models adjusted for potential confounders.
Overall 5-year survival following OPC diagnosis was 50%o. HPV16-positive OPC cases were at significantly lower
risk of death (HR:0.49, 95ohCl:0.34- 0.70). A significant effect on OPC survival was apparent for female sex (HR
0.52: 95o/o CI; 0.3- 0.91) and being underweight at diagnosis (HR: 2.43, 95oh CI: 1.4- 4.22). A l0 pack year smoking
history was not associated with survival. This study confirms that HPVI6 status is an independent prognostic factor
for OPC survival while female sex lowers risk of death and being underweight at diagnosis increases the risk of
death. Smoking was not an independent predictor of OPC survival.
Key message
The role of patient-related factors in oropharyngeal cancer survival is unclear. Here we show that in addition
HPVI6 status and disease stage, being female was associated with nearly 50% reduced risk and low BMI
diagnosis almost doubled the risk of death following oropharyngeal cancer.
Key words: Oropharynx cancer, HPV 16, survival, tobacco, body mass index, gender
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Introduction
Cancers arising in the oral cavity and pharynx have an estimated global burden of 442,760 incident cases and
241,458 deaths each year[]. Tobacco smoking and alcohol consumption explain nearly 70%o of these cancers[2, 3].1
Infection by human papillomavirus (HPV), particularly type 16 GIPVI6) causes a subset of cancers, particularly
those arising at the tonsil, oropharynx, soft palate and base ofthe tongue (collectively referred to as oropharyngeal
cancers-OPC)[4]. Further, HPVl6-positive (HPVl6+) OPC is described to be epidemiologically, molecularly and
clinically distinct from HPVl6-negative (HPVI6-) OPCt5l. The increasing incidence of OPC in several Westem
countries is athibuted to the HPV16+ fraction[6-9].
Since HPVI6+ OPC patients experience better survival outcomes compared to HPVI6- patients, alternative stagidg
has been recommendedtl0-l2]. Recurrence remains a concem and it is unclear which patients may benefit from de-
intensified treatment. Clinically, HPV status is ascerlained based on HPV DNA and p16 expression or pl6
expression alone. HPV status in combination with disease stage and patient smoking history @ased on a l0 or 20
pack year cut off) is currently used to classi$ patients into prognostic groups and to identifu candidates for de-
escalation of treatment[0, l3]. This scheme has rarely been verified. Further, the appropriate cut-point for pack
years of smoking remains uncefiain. tn addition, the role of other non-clinical risk factors in OPC survival is not
fully understood.
To address these knowledge gaps, we tested 321 oropharyngeal tumors in a large series of well characterized
European patients for HPVI6 DNA, pl6 expression and the corresponding sera for HPV16 serology. Applying
rigorous protocols of sample processing; we aimed to evaluate the role of HPV16 and other risk factors in predicting
OPC survival and recurrence.
Methods
This analysis was based on cases from the European Alcohol Related Cgncers and Genetic susceptibility il Europe
(ARCAGE) study, conducted across l0 countries in Europe using a standardized protocol [14]. Briefly, over 2000
incident cases of the oral cavity, pharynx. larynx, esophagus and matched controls were recruited during 2002 to
2005. This analysis included squamous cell carcinoma of ICD-O diagnoses C01,C02.4, C05.1- C05.2, C09, Cl0. All
participants underwent personal interviews to record lifestyle exposures. All cases were histologically or
cytologically confirmed primary cancers, and cancer stage was ascertained based on the sixth edition of the staging
atlas developed by the American Joint Committee on Cancer (AJCC). Tobacco use was broadly categorized as ever
or never smokers, ever smokers were defined as individuals who smoked any tobacco product at least once a week
for a year. Pack years were calculated for all types oftobacco smoking based on clgarette equivalents. Ever drinkers
were those who reported ever consumption of any alcoholic beverage and the consumption of all types of alcoholic
beverages was estimated and the total frequency was expressed in terms of drinks of alcohol per day [5]. A
weighted composite score of oral hygiene and dental care was constructed as described previously [ 1 6] and included
denture wear, age at start of denture-wearing and gingival bleeding. A weighted dental care score was also
constructed by combining the frequency of tooth cleaning, use of toothpaste, toothbrush or dental floss and
frequency of dentist visits, where the maximum score of eight reflected poor dental care. Body mass index was
calculated based on weight measured at the time of recruitment. BMI ranging fiom 18.5 to 25.0 was considered
normal, below 18.5 underweight while >25.0 was considered overweight. Informed consent was obtained from ali
participants in the study and the study was approved by the ethical review boards at the participating centers.
Preffeatment serum samples were tested for HPV antibodies using the bead-based multiplex serology method [ 17,
l8l. We have previously shown that HPV16 E6 antibody is a highly specific marker of HPVI6+ OPC with false-
positive rates less than lYo[L1, 19-211. For comparison, 198 paraffin-embedded OPC tumor blocks were qualitatively
evaluated for pl6 expression using the CINtec Histology Pl6INKaa Kit (9511, mtmlabs) following manufacturer's
instructions. Expression was scored based on the percentage and intensity of nuclear or cl.toplasmic staining, A
combined score of 4 or greater was considered positive for p1(tNraa overexpression. HPV genotyping was performed
using the Type-Specific E7 PCR bead-based multiplex assay (TS-E7-MPG, IARC, France)[17, 22f . Given that HPV
serology was available on all cases; our analysis defined a HPV+ tumor as HPVI6 E6 antibody positive. We
subsequently compared this to tumor results based on p16 expression and HPV DNA.
Participants underwent a one-time follow-up conducted between 2012 and 2015. Mortality data including cause and
date of death were obtained from at least two information sources for 7 5Yo of cases, and one source for the remaining
25Yo.ln Prague and Aviano follow-up was completed by review of medical charts alone. In all other centers, medical
chart reviews together with information from population-based registries at the regional or national level were used.
In Athens, Barcelona and Manchester physicians were contacted to obtain patient outcome information, while in
Oslo, Zagreb and Glasgow cancer registries were consulted. In Bremen, Turin, Padova and Dublin mortality
registries were examined. End of follow-up was defined as the date of last confirmed contact, vital status at censor,
or date of death (if applicable). Over 96%o of OPC patients' recruited in the study have complete follow-up. Overall
survival (all-cause moftality) was evaluated using Cox proportional hazard models, predictors were explored for
OPC overall and stratified by stage, sex and HPVI6 status. Mortality was also explored using Kaplan Meier curves.
The joint effects on survival were considered by combining cofactors in interaction models. We used chi-squared
tests to examine heterogeneity in hazard estimates. All statistical analyses were performed using STATA statistical
software, version 11 (StataCorp, College Station, TX), and all reported P values are two sided. Statistical
significance was set at P less than 0.05.
Results
Subjects were primarily male (7'7%), ever smokers (90o ), alcohol drinkers (97%) and had a median age at diagnosis
of 58. The vast majority of OPC were diagnosed at late stages; 49o/oinstage IV, 25Yoinstage III and26%oin stages I
and II. 31% of OPC cases were HPVI6 E6 positive. OPC subjects were followed for 1257 person years during which
175 deaths occurred (mean follow-up of 3.92 years), of which 98 (560/o) were due to head and neck cancer.
Overall S-year survival tbllowing OPC diagnosis was 50% (g5% CI: 43.9- 54.9). As described in table l, in the
univariate analyses there was significantly lower risk of death among 99 HPVI6+ compared to 222 HPV- OPC
(HR:0.49, 95YoCl: 0.34- 0.70). Five-year overall survival was 650/o among HPV16+ compared to only 43Yo among
HPV16- OPC (p<0'001, Figure l). Other significant risk factors associated with OPC survival included female sex
(HR 0.52, 95o/o CI: 0.35- 0.78), older age at diagnosis (HR: 1.24, 95%, CI: 1.05- 1.45), smoking (HR 2.24, 95Yo Cl:
1.39- 3.60), alcoholuse (Hk 1.53 ,95yo CI: 1.13- 2.06), moderate dental care (HR: 1.58,95%CI: 1.10- 2.29),being
underweight at diagnosis (FIR: 2.25, 95Yo Cl: 1.38- 3.67) and late stage disease (HR: 2.84, 95Yo Cl: 1.78- 4-55)
(Table l). When these covariates were combined in a single model, the risk of death remained significant lower
among HPV16+ compared to HPVI6- OPC (aHR: 0.51,95%CI: 0.32- 0.80, Table 1). In addition, a significant effect
on OPC survival was apparent for female sex (aHR 0.5O:95Yo Cl:0.29- 0.85), being underweight at diagnosis (aHR:
2.41,95o CI: 1.38- 4.21) and higher disease stage (aHR: 2.63,95yo CI: 1.61- 4.03), but not for smoking (HR: 1.1 1,
95Yo Cl:0.59- 2.09), moderate dental care (aHR: 1.09, 95Yo CI 0.72- 1.65), age (HR:l .17,95Yo CI: 0.95- 1.44) or
alcohol use (HR: 1.02,95yo CI:0.69- 1.51) (Table l).
We further examined the robustness of the associations of being female or being underweight and OPC survival. No
difference was observed in the association between being female and OPC survival among HPVI6+ (HR: 0.30, 95%
CI:0.09- 0.95) orHPVl6- OPC (HR:0.67,95yo CI:0.36- 1.37,(P-heterogeneity:0.22).Conversely, the increased
risk of death associated with being underweight at diagnosis was consistent for stage I and II (HR: 1.51, 95o/oCl:
0.17-13.30), stage III (HR: 4.94, 95ohCl:1.77-13.81) and stage IV disease (HP.:2.22,95%Cl:1.08-4.55), with no
heterogeneity in the estimates (p for heterogeneity: 0.39). We further examined these findings in the context of the
recently proposed staging for HPV+ OPC that combines disease stage at diagnosis, age and smoking pack-years into
four groups with differing prognosis; group I comprising of stage I-I[ OPC patients' with < 20 pack years, group II
of stage I-III patients' with >20 pack years, group III were stage IV and <70 years old and group IV were stage IV
with >70 years of age [0]. Consistent with the initial report, overall survival decreased across these groups (data not
shown). Notably, female sex (HR: 0.54,95o/o CI: 0.33- 0.88) and being underweight at diagnosis (HR for: 2.59,95yo
CI: 1.50- 4.46)remained consistently associated with OPC survival, independent of the suggested prognostic risk
classification.
Unlike previously published studies, the lack of association of smoking with overall survival following OPC
diagnosis was consistent (supplementary table 1). Although metrics of smoking exposure were associated with
higher risk of death among OPC patients' in the univariate analysis (e.g. HR for 10 pack year cut-point:2.24.95o/o
CI: 1.39-3.60), none of the associations remained significant in the multivariable models. Inclusion of stage and
HPV16 status in the models significantly mitigated the effect for smoking (bHR for l0 pack year cut-point: 1.46,
95o/o Cl: 0.80-2.69). Further, we observed no interaction between smoking and HPV16 status in the risk of death
following OPC diagnosis (P-interaction: 0. 50).
There were 84 recurrences among 260 cases with an average follow-up of 4.2 yearc. The risk of recurrence was
lower in 82 HPV I 6+ than I 78 HPV I 6- OPC (HR: 0.59:' 95%o CI: 0.36- 0.96, aHR: 0.55:. 95Vo CI: 0.29- I .06, Table
2). Three year recurrence-free survival was 77o/o in HPVI6+ and 660/o in IIPV16- OPC (P:0'03, Figure 2). The only
other factor associated with OPC recurrence was advanced stage disease (HR for stage IV OPC: 4.88; 95o/o Cl:2.12-
11.21). 27% (22/82) of patients with HPV16+ OPC had recurrence within the follow-up period. Other factors
associated with progression among HPVI6+ OPC included moderate dental care (HR: 3.98, 95oh Cl: 1.19- 13.35)
and advanced disease stage (HR for stage IV OPC: 7 .54, 95yo Cl: | .23 - 46 .13).
In this study, 198 corresponding tumors of 321 cases were tested for HPV DNA and p16 expression. Of these, 16
were excluded due to limited tissue. Of the remaining 156 tumors, 52 were HPV16 E6 seropositive of which 43 were
positive for both HPV16 DNA and p16 expression while 44 were positive for p16 expression alone (Table 3).
Among the 104 HPVI6 E6 seronegative cases, 98 were HPVI6 DNA or pl6 negative while 84 were p16 negative.
The agreement between HPVI6 E6 serology and the combined marker (91%) was better compared to p16 alone
(82%)(Table 3). In the univariate analysis, tumor HPV16 DNA positivity alone was marginally associated with OPC
survival (HR:0.66,95YoC\:0.43- 1.02), while tumor pl6-positivity alone (HR: 0.59,95yo CI:0.38- 0.94) or dual
positivity to HPVI6 DNA and pl6 (HR: 0.48,95o/o Cl: 0.29- 0.81) were significantly associated with OPC survival.
The strongest association with survival however, was observed among OPC subjects who were HPVI6 E6 serology
positive (HR:0.44, 95Yo Cl: 0.26- 0.74).In the fully adjusted model however, only the association between F{PVl6
E6 serology and OPC survival remained significant (HR: 0.39, 95o/o Cl: 0. l9- 0.71 ) (Table 4).
Discussion
This study confirms I-IPVI6 status as an independent prognostic factor for overall survival and recurrence-free
survival among OPC patients'. We also report that women are at lower risk of death (both [IPV+/FPV-), while being
underweight at diagnosis increases the risk of death following OPC diagnosis.
The reduction in risk of death among HPV16+ OPC in this study was similar in magnitude to previous studies [3,
231. Our results indicate that additional factors may have an important effect in predicting survival following OPC.
In particular that women may have approximately 50% reduced risk of death compared to men following an OPC
diagnosis. Importantly, this benefit was extended to late stages of disease and was consistent for both HPVI6+ and
HPVI6- OPC suggesting the protective effect may be driven by inherent factors. Although an individual's gender has
been long recognized as a key factor affecting cancer incidence, prognosis, and treatment response, the underlying
mechanisms remain poorly understood. We also report that being underweight at diagnosis increases the risk of death
following OPC by over two-fold. This association was robust across stage, sex and HPVI6 status. Although it
remains probable that low BMI at diagnosis reflects the disease itself, since cancer patients tend to lose weight
rapidly following disease onset, it could also point towards the need for nutritional interventions prior to clinical
treatment as a strategy towards potentially improved outcomes. The lack of association with low BMI at 30 years of
age and OPC survival in this study (data not shown) supports this notion. lt remains important to note that both low
BMI at diagnosis as well as female sex remained independently associated even when considering the recently
proposed progrrostic risk classification for OPC. These findings warrant further validation in independent studies.
Previous studies have found tobacco smoking to be independently associated with overall survival as well as
progression-free survival among OPC patients[s, 10, 13, 24]. Smoking, in particular, 10 or 20 pack year thresholds in
conjunction with"tumor stage and FIPV status have therefore been proposed for risk stratification and [0, l3]to
identifu patients who may benefit from keatment de-escalation. In this study, the lack of association between
smoking and OPC survival was consistently observed irrespective of the smoking parameter examined (i.e., smoking
status, or varying definitions for pack years including increments of I pack year, 10 pack years or tbresholds of 10
and 20 pack years). Sequential adjustment of covariates indicates that tIPVl6 status and disease stage could
potentially account for the survival differences due to smoking. Further, we found no interaction between smoking
and HPV16 status in the risk of death following OPC. These results call for additional evidence in larger cases series
in order to accurately establish the role of smoking and survival among HPVI6+ OPC.
This study demonstrates a strong association between HPV 16 status and OPC survival. Even though p I 6 and HPV I 6
DNA each showed utility in predicting mortality, they both appeared to be sub-optimal proxies for HPV16 status.
While the utility of tumor HPV16 DNA and pl6 as diagnostic markers of OPC is now well established [25-27], this
study confirms the utility of HPVI6 E6 serology as a robust prognostic marker of OPC.
Despite the advantage of the multi-centric design and the large number of participants enrolled in the parent study,
the OPC subset was limited to 321 cases. Even so, to the best of our knowledge, this remains among the largest
analysis of this rare can€er with detailed information on risk factors, patient outcome as well as HPV16 status.
Important strengths of this study are the centralized testing for HPV16, uniform collection of survey and cancer
outcome information in all centers. Some of the limitations include the absence of detailed ffeatment information that
could potentially impact survival. However, the majority of the patients' were treated with surgery alone or in
conjunction with chemotherapy or radiation therapy (68%). Further, disease stage was missing on 16%o of OPC since
the study was initially designed with a focus on risk factors for cancer occurrence, therefore comprehensive
collection of clinical data was not emphasized.
In conclusion, this study confirms the markedly improved prognosis associated with HPV+ OPC in Europe. In
addition, we report that being female and low BMI at diagnosis are important factors affecting overall OPC survival.
Further large studies that also include comprehensive mutational profiling will be required to better understand the
mechanisms underlying these prognostic subgroups.
Conflict of interest statement:
The authors declare that they have no conflict of interest'
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Table l: Univariate and multivariate analyses of risk factors associated with death in 321 oropharyngeal
cancer patients
Univariate
Characteristics Dead/ Total HR (95% CI)
lVlultivariate
aHR(95% CD
(N=32r)
HPVI6 E6 Serology
Negative
Positive
Sex
1361222 1.0 1.0
39199 0.49 (0.34- 0.70) 0.sl (0.32- 0.80)
Male ru7/247 1.0 t.0
Female 28774 0.52 (0.3S- 0.7S) 0.50 (0.29- 0.S5)
Age (10 year increase) t.24 (1.05- f .45) l.l7 (0.95- 1.44)
Smoking status"
<10 Pack-years 19/58 1.0 1.0
>10 Pack-years 1551262 2.24 (1.39-3.60) l.1l (0.59- 2.09)
Alcohol useb
52 drinks/ day 75/l5g 1.0 1.0
>2 drinks/ day 99/160 1.53 (1.13- 2.06) 1.02 (0.69- 1.51)
Dental care"
Good 36/84 1.0 1.0
Moderate 134/231 1.58 (1.1- 2.29) 1.09 (0.72- t.65)
Poor 3/4 2.45 (0.76- 7 .98) 0.46 (0.06- 3.44)
BMI at diagnosisd
Normal) 83/161 1.0 1.0
Underweight 20/25 2.2s (1.38- 3.67) 2.41(1.38- 4.21)
Overweight 611108 l.0l (0.73- 1.41) 1.12 (0.77- 1.63)
Stage"
I&rr 22/71 1.0 1.0
ilr 3st67 2.02 (1.18- 3.44) 1.78 (1.02- 3.10)
rv 85/13r 2.84 (t.78- 4.ss) 2.63 (1.61- 4.30)
aHR: adjusted mutually for all covariates in the table, and additionally for center of recruitment
" 1 case missing smoking information
b 2 cases missing alcohol data
" 
missing information on 2 cases
d missing information on 27 cases
"missing stage on 52 cases
10
Table 2: Univariate and multivariate analyses of risk factors associated with recurrence in 260 oropharynx
cancer patients
Characteristics HR (957o CI) aHR (957o CI)
FIPVI6 E6 Serology
Negative I I
Positive 0.59 (0.36-0.96) 0.55 (0.29- 1.06)
Sex
Male I I
Female 0.86 (0.52-1.40) 1.04 (0.52- 2.09)
Age (10 year increase) 1.13 (0.89- 1.43) 1.03 (0.77- 1,38)
Smoking status
<10 Pack-years I I
>10 Pack-years 1.38 (0.79-2.43) 0.65 (0.30- l.4l)
Alcohol use
52 drinksi day I 1
>2 drinks/ day 1.33 (0.87- 2.04) 0.99 (0.55- 1.81)
Dental care
Good I I
Moderate 2.25 (1.29- 3.95) 1.82 (0.96- 3.45)
Poor 1.77 (0.23-13.42) 1.19 (0.1s- 9.69)
BMI at diagnosis
Normal I I
Underweight 0.85 (0.30-2.36) 0.82 (0.27- 2.43)
Overweight 0.82 (0.51- I .32) 0.74 (0.43- 1.27)
Stage
r&[
III
IV
11
2.12 (0.98-4.s9) 2.89 (1.r8- 7.06)
3.22 (1.61-6.44) 4.88 (2.12- 11.21)
aHR: adjusted mutually for all covariates in the table, and additionally for center of recruitment
TL
Table 3: Concordance between serolog5r and tumor markers of HPV16 infection in 153 oropharyngeal cancer
patients
Tumor marker
ITPV16 E6
serology
Positive Negative
N:52 nr:104
ITPV16 DNA/
pI6 status
Positive
Negative
p16 status
Positive
Negative
AgreemenF 9l7o
436
998
Agreement:82%o
44 20
t2
Table 4: Multivariate analysis of the association between markers of HPVI6 infection and risk of death in 235
oropharyngeal cancer patients
Dead/
HPV marker Total HR (95% CI) aHR (95% CD
TIPVl6 DNA
Positive 41169 1.0 1.0
Negative 4ll 84 0.66 (0.43- 1.02) 0.77 (0.43- 1.35)
pl6
Positive 54/ 89 1.0 1.0
Negative 28/ 64 0.59 (0.38- 0.94) 0.72 (0.42- 1.24)
HPV16 DNA/ pl6
Positive 631 102 1.0 1.0
Negative 19/ 51 0.48 (0.29- 0.8r) 0.63 (0.35- 1.15)
HPV16 E6
Positive 631 104 1.0 1.0
Nesative 191 49 0.44 (0.26- 0.741 0.36 (0.19- 0.71)
aHR: adjusted fbr age, sex, smoking pack years, alcohol drink years, dental care, stage and center
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Figure l(a): Overall survival among 321 oropharyngeal cancer patients' by HPVI6 E6 status
Figure legend:
Cumulative survival of all-cause mortality among patients diagnosed with oropharyngeal cancer by human
papillomavirus type l6 (HPV16) E6 serology status. Patients who were seropositive (solid line; N:99) and
seronegative (broken line; N :222) for HPVI6 were compared for all-cause mortality.
Figure 1(b): Recurrence-free survival of260 oropharyngeal cancer patients by HPVI6 E6 status
Figure legend:
Recurrence-free survival among 260 patients diagnosed with oropharyngeal cancer by human papillomavirus type l6
(HPV16) E6 serology status. Patients who were seropositive (solid line; N:82) and seronegative (broken line;
N:178) for HPVI6 were compared for all-cause mortality.
t4
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